Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Weber M
Authors: Fottner C, Apostolidis L, Ferrata M, Krug S, Michl P,
Keywords: NEC, NEN G3, check-point inhibitor, Avelumab, anti-PD-L1-antibody, immunotherapy,
#2769 Treatment Outcomes of Patients with G3 Neuroendocrine Neoplasms
Introduction: Extra-pulmonary neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) G3 are aggressive neoplasia associated with a limited prognosis.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Jann H
Authors: Schenk J, Kayser A, Wiedenmann B, Tacke F, Roderburg C,
Keywords: NEN G3, Chemotherapy, Platinum, NEC G3, NET G3,
Introduction: Rectal neuroendocrine carcinomas (NEC) are extremely rare and account for less than 1% of colorectal malignancies.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Della Torre S
Authors: Lombardi P, Grandi S, Marinelli M, Manara M, Della Torre S,
Keywords: rectal nec, net, chemotherapy, metastatic disease,
Introduction: The update of the WHO 2017 classification of pancreatic neuroendocrine tumors (NETs) introduces the distinction between NET & NEC G3, based on histological differentiation. However, little is known about the possibility of extending this concept to non-pancreatic NETs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Castaño A, Capdevila J, Benavent M,
Keywords: WHO classification, NET G3, NEC G3, non-pancreatic NET, poorly differentiated,
Introduction: G3 gastroenteropancreatic neuroendocrine tumors (G3 NET) and carcinomas (G3 NEC) differ considerably concerning their biological behavior and patients outcome. Whereas the WHO2017 classification for pancreatic NETs proposes a distinction of both groups using the Ki-67 proliferation marker (Klöppel et al. Reviews and Reports 2017), a useful marker for the subclassification of G3 intestinal NETs have not been recommended until now.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Briest F
Authors: Briest F, Konukiewitz B, Anlauf M, Klöppel G, Grabowski P,
Keywords: gastroenteropancreatic neuroendocrine tumors, GEP-NET, NET G3, NEC G3, Tumor marker, FOXM1, Ki-67, differentiation,